Aptose Biosciences Inc.

    Aptose Biosciences Inc.

    NNASDAQ:APTO
    1.71
    USD
    0.00
    (0.00%)
    Aptose Biosciences Inc.
    NASDAQ:APTO
    (Nasdaq Stock Market)

    Recent

    price

    1.71

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2009
    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    TTM
    USD
    110.69
    71.6
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Revenue per Share
    -5,330.12
    2,913.79
    -2,099.09
    -1,193.69
    -690.1
    -839.06
    -442.64
    -502.88
    -234.81
    -389.05
    -235.74
    -303.74
    -330.12
    -203.98
    -227.43
    -36.38
    -19.37
    Basic EPS, GAAP
    -4,445.18
    -2,034.9
    -2,450.41
    -856.59
    -631.07
    -680.44
    -383.6
    -437.65
    -206.44
    -317.19
    -194.32
    -186.79
    -219.81
    -157.76
    -198.17
    -51.48
    -24.53
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -16,345.92
    -11,018.93
    -8,822.05
    -6,301.66
    -3,154.37
    192.89
    -324.26
    -603.63
    -299.43
    -196.3
    570.35
    397.95
    75.16
    -130.76
    -314.14
    -119.55
    -78.77
    Book Value per Share
    -5,388.48
    -627.47
    -154.23
    -524.66
    -96.85
    2,261.16
    514.17
    257.92
    205.75
    189.77
    842.64
    653.89
    374.99
    184.07
    -12.88
    -6.5
    -6.71
    Tangible Book Value per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    -3,894.57
    -4,345.04
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    1
    - -
    - -
    - -
    Depreciation Expense
    -8
    5
    -5
    -4
    -5
    -10
    -12
    -14
    -12
    -29
    -26
    -55
    -65
    -42
    -51
    -25
    -21
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -4,815.22
    4,069.47
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -8
    -1
    - -
    -2
    -1
    27
    13
    7
    10
    14
    93
    118
    74
    37
    -3
    5
    1
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    - -
    1
    1
    10
    9
    LT Debt
    -8
    -1
    - -
    -2
    -1
    26
    14
    7
    10
    14
    94
    119
    74
    38
    -3
    -5
    -7
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -81.27
    -149.81
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    10
    10
    8
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    1
    2
    3
    Market Capitalization
    7
    4
    3

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    Total Current Assets
    10
    10
    7
    Cash, Cash Equivalents & STI
    - -
    6
    5
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    10
    4
    6
    Payables & Accruals
    9
    4
    6
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    43.88%
    -22.24%
    56.6%
    Free Cash Flow
    23.32%
    15.57%
    -19.36%
    Net Income, GAAP
    22.73%
    12.92%
    -50.34%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -66.49
    -67.99
    -52.87
    - -
    -227.43
    2024
    -22.02
    -12.98
    -11.24
    - -
    -36.38
    2025
    -2.61
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

    • globenewswire.com

      Aptose Reports First Quarter 2026 Results

    • defenseworld.net

      Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?

    • defenseworld.net

      Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

    • globenewswire.com

      Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

    • defenseworld.net

      Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?

    • globenewswire.com

      Aptose Announces Auditor Not Standing for Re-Appointment

    • globenewswire.com

      Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

    • globenewswire.com

      Aptose Reports Year End 2024 Results and Corporate Highlights

    • globenewswire.com

      Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

    • benzinga.com

      Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?

    • globenewswire.com

      Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

    • globenewswire.com

      Aptose Announces Reverse Share Split

    • globenewswire.com

      Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

    • globenewswire.com

      Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

    • globenewswire.com

      Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

    • globenewswire.com

      Aptose Announces Positive Decision by Nasdaq Hearings Panel

    • globenewswire.com

      Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

    • globenewswire.com

      Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

    • globenewswire.com

      Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials